(Q47770450)

5 February 2018

title

Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin (English)

1 reference

5 February 2018

1 reference

1 reference

4

1 reference

5 February 2018

author name string

Albrecht Fiesselmann

series ordinal

1

1 reference

5 February 2018

Tobias Wiesner

series ordinal

2

1 reference

5 February 2018

Holger Fleischmann

series ordinal

3

1 reference

5 February 2018

publication date

19 April 2016

1 reference

5 February 2018

published in

Acta Diabetologica

1 reference

5 February 2018

volume

53

1 reference

5 February 2018

issue

5

1 reference

5 February 2018

page(s)

717-726

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1007/s00592-016-0862-0

exact match

0 references

cites work

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Insulin therapy in people with type 2 diabetes: opportunities and challenges?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Evolution of diabetes insulin delivery devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

Insulin pen-the "iPod" for insulin delivery (why pen wins over syringe)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-016-0862-0

10.1007/S00592-016-0862-0

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018